Published Paper Details:

Although proton pump inhibitors (PPI) have a record of remarkable effectiveness and safety in the management of gastroesophageal re?ux disease (GERD), several treatment challenges with PPI have emerged. Dexlansoprazole is the (R)-enantiomer of lansoprazole contained in a formulation that produces two distinct drug releases and significantly increases the duration of active plasma concentrations and percent time pH 4 compared to conventional single-release PPI. In most patients, dexlansoprazole can be taken without regard for meals or meal timing. Dexlansoprazole 60 mg showed comparable efficacy for healing of erosive esophagitis at 8 weeks compared to lansoprazole 30 mg, and dexlansoprazole 30 mg was superior to placebo for maintenance of healed erosive esophagitis at 6 months, with 99 percent of nights and 96 percent of days heartburn-free in patients taking dexlansoprazole 30 mg. The safety pro?le of dexlansoprazole is similar to that of lansoprazole. The extended pharmacodynamic effects, added convenience, and ef?cacy and safety of dexlansoprazole offer a novel approach to gastric pH control in patients with acid-related disorders.